Erythrocytosis on TRT
Dose-Dependent Hematocrit Rise, the 54% Threshold, and Thrombosis Risk
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Erythrocytosis is a labeled adverse effect of all testosterone products; not a separate drug
Reference only. Not medical advice.
What can go wrong
Elevated hematocrit raises whole-blood viscosity and is associated with venous thromboembolism (DVT, pulmonary embolism) and, in epidemiologic data, with arterial events. The TRAVERSE trial (Lincoff 2023) found a numerically higher rate of pulmonary embolism with testosterone (0.9% vs 0.5%). However, much of the thrombosis literature is confounded, and whether moderate isolated erythrocytosis independently causes events at TRT-range hematocrits is not settled. Sleep apnea, smoking, and dehydration compound the risk.
This is something to take to a clinician. The Atlas can tell you what is known about erythrocytosis on trt in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Erythrocytosis (secondary polycythemia) is the most frequent dose-limiting adverse effect of testosterone therapy. Testosterone suppresses hepcidin and stimulates erythropoiesis, raising hematocrit and hemoglobin in a dose- and peak-dependent fashion. The Endocrine Society 2018 guideline (Bhasin et al.) and AUA 2018 guideline both treat a hematocrit above 54% as a trigger to stop or reduce testosterone until it normalizes. The clinical concern is hyperviscosity and venous/arterial thromboembolism, though the magnitude of attributable thrombotic risk from isolated TRT-induced erythrocytosis remains debated.
The single most common dose-limiting side effect of testosterone, and the most-argued-about number on a TRT lab panel.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
Testosterone increases erythropoiesis through at least two pathways: it suppresses hepcidin (raising iron availability for red-cell production) and modestly stimulates erythropoietin, resetting the EPO-hemoglobin set point upward. The rise is dose-dependent and peak-dependent: large infrequent intramuscular doses produce the highest hematocrit, transdermal and frequent low-dose subcutaneous regimens the least. The effect plateaus over months and is largely reversible on dose reduction.
- Onset of rise
- Weeks to a few months
- Plateau
- ~3-12 months
- Largest rise with
- IM testosterone enanthate/cypionate, q2-3wk
- Smallest rise with
- Gel; frequent subQ
Safety in detail
This intervention involves significant physiological effects and requires evaluation and monitoring by a qualified physician. Self-administration without medical oversight carries documented health risks. Ignoring a rising hematocrit, or self-treating it with phlebotomy while maintaining an excessive dose, is dangerous.
Replacement is not the same as a cycle
Erythrocytosis scales steeply with testosterone exposure. Physiological replacement targeting mid-normal trough levels produces modest, manageable rises; supraphysiological/anabolic dosing markedly increases the incidence and severity of polycythemia and the resulting hyperviscosity/thrombosis risk.
What it does to fertility
Erythrocytosis itself has no direct fertility effect; fertility is governed by the underlying testosterone exposure suppressing the HPG axis and any hCG/SERM adjunct.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Hematocrit and hemoglobin (CBC) at baseline, 3-6 months, then annually
- Total testosterone (trough)
- Ferritin/iron studies if recurrent phlebotomy
- Blood pressure
- Screen for obstructive sleep apnea and smoking
What people get wrong
Often saidA high hematocrit on TRT is harmless as long as you feel fine
ActuallyErythrocytosis is usually asymptomatic until it is severe; both the Endocrine Society and AUA treat >54% as an action threshold regardless of symptoms.
Often saidDonating blood every couple of months fully solves it
ActuallyVoluntary donation is capped at roughly every 56 days and may not keep pace with a high-peak protocol; the durable fix is lowering dose or smoothing peaks, with phlebotomy as adjunct.
Often saidErythrocytosis means your TRT is working well
ActuallyIt is a dose-related toxicity, not a marker of benefit; it most reflects excess exposure or an unfavorable delivery route.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
What we do not know
- What absolute hematocrit and viscosity threshold actually drives thrombotic events at TRT doses?
- Does testosterone-induced erythrocytosis carry the same prognosis as primary polycythemia vera?
- Is the PE signal in TRAVERSE causal or confounded?
At a glance
- Guideline action threshold
- Hematocrit >54% (stop/reduce per Endocrine Society 2018 & AUA 2018)
- Mechanism
- Hepcidin suppression + erythropoiesis stimulation
- Highest risk route
- Intramuscular injection (high peaks)
- Lower risk routes
- Transdermal gel, subcutaneous, lower/more-frequent dosing
- Reversible
- Yes, with dose reduction or cessation
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Erythrocytosis on TRT. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Endocrine Society Clinical Practice Guideline (Bhasin et al., JCEM)2018
Recommends measuring hematocrit at baseline, 3-6 months, and annually; evaluating/stopping testosterone if hematocrit exceeds 54%
TRAVERSE (Lincoff et al., NEJM)2023
Pulmonary embolism numerically more common with testosterone (0.9% vs 0.5%); MACE noninferior
Ohlander et al. review of testosterone and erythrocytosis (Sex Med Rev)2018
Synthesizes route- and dose-dependence of hematocrit rise and management options